Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stanford V Chemotherapy in Unfavorable Hodgkin's Disease
NCT00002715Phase 2Completed
- Sponsor
- Stanford University
- Start
- Apr 1989
- Primary completion
- Jan 2007
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin and 2 more in Hodgkin lymphoma (HL), sponsored by Stanford University. Primary endpoint: Feasibility of Stanford V Regimen at 12 weeks. Started Apr 1989; status: completed.
02
Drugs
mechlorethaminedoxorubicinvinblastinevincristinebleomycin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00002715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002715.